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Abstract
Use of historical data in clinical trial design and analysis has shown various advantages
such as reduction of within-study placebo-treated number of subjects and increase of study
power. The meta-analytic-predictive (MAP) approach accounts with a hierarchical model
for between-trial heterogeneity in order to derive an informative prior from historical (often
control) data. In this paper, we introduce the package RBesT (R Bayesian Evidence
Synthesis Tools) which implements the MAP approach with normal (known sampling
standard deviation), binomial and Poisson endpoints. The hierarchical MAP model is
evaluated by MCMC. The numerical MCMC samples representing the MAP prior are
approximated with parametric mixture densities which are obtained with the expectation
maximization algorithm. The parametric mixture density representation facilitates easy
communication of the MAP prior and enables via fast and accurate analytical procedures
to evaluate properties of trial designs with informative MAP priors. The paper first
introduces the framework of robust Bayesian evidence synthesis in this setting and then
explains how RBesT facilitates the derivation and evaluation of an informative MAP prior
from historical control data. In addition we describe how the meta-analytic framework
relates to further applications including probability of success calculations.
Keywords: Bayesian inference, clinical trial, extrapolation, historical control, operating char-
acteristics, prior, probability of success, robust analysis.
1. Introduction
More efficient clinical trials are of great demand in drug development for all players like phar-
maceutical companies, regulatory agencies, health-care organizations and, most importantly,
for patients. Use of historical data for quantitative trial design has become more and more
attractive for the same reason (Wandel et al. 2015; Neuenschwander and Schmidli forthcom-
ing). Using historical data can reduce the size of the control group, leading to a smaller size
of clinical trials which are more ethical and shorten study duration. Therefore, studies uti-
lizing historical data may speed up informative decision making and eventually make better
medicines available to patients sooner.
Borrowing information from historical studies has always been a part of the design of clinical
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2 Applying MAP Priors with RBesT
trials. For example, the definition of a patient population in a new clinical study compared
to previous similar studies, or how much of a clinically relevant treatment effect to expect
compared to the placebo treatment. Contributions from statisticians in a more quantitative
manner started more than 40 years ago, by Pocock (1976). Since then, the relevant statistical
approaches have been developed by many, mostly in a Bayesian framework (Chen and Ibrahim
2000; Spiegelhalter et al. 2004; Neuenschwander et al. 2010; Hobbs et al. 2012).
In this paper, we focus on robust meta-analytic-predictive (MAP) priors (Neuenschwander
et al. 2010; Spiegelhalter et al. 2004), which is a hierarchical modeling method allowing het-
erogeneity between historical trials. As in any meta-analytic approach, it is important to first
examine the characteristics of the historical trials with clinical inputs. These include quantita-
tive descriptions of trial population such as subject demographics and baseline characteristics
and qualitative features such as concomitant medications. This would help to ensure selected
historical controls would be as similar as possible to those in the new trial, such that one of
the key assumptions of exchangeability between the trials holds. Secondly the assumption
for between-trial heterogeneity needs to be reasonable, which can be checked via sensitivity
analysis using different priors for the heterogeneity parameter. This assumption of between-
trial heterogeneity should also be agreed with clinical colleagues. Then the MAP prior can be
derived from a random-effect meta-analysis of historical data via Markov Chian Monte Carlo
(MCMC) algorithms, which is computationally convenient. The predictive distribution will
be used to construct the informative prior for the within-study control. The interpretation of
using these historical control data can be expressed as the effective sample size of the predic-
tive distribution, i.e. a discounted sample size from the historical control data. Incorporation
of this information can therefore save this number of subjects in the control group of the
new study. Robustification of the predictive prior (Schmidli et al. 2014) is recommended to
deal with possible deviation between historical control and the control within the new study.
Application of the MAP approach to incorporate historical data in early phase clinical trials
has been more widely accepted, not only by statisticians but also in medical societies (Baeten
et al. 2013).
In this R package, R Bayesian evidence synthesis tools, RBesT, we implement the MAP ap-
proach via rstan (Stan Development Team 2018). The package supports endpoints including
normal, binary and count and a number of different prior distributions for the between-trial
heterogeneity parameter. We approximate the MAP MCMC prior using a parametric mix-
ture distribution which is obtained via the expectation maximization (EM) algorithm. The
robustification of the MAP prior is implemented by adding one more weakly-informative com-
ponent to the mixture. The package also supports inclusion of covariates in the meta-analysis.
Functions for running analysis of operating characteristics are built in a very intuitive manner.
Several R packages exist for meta-analysis, such as netmeta using a frequentist approach
(Rücker 2012), bayesmeta for random-effect meta-analysis (Röver 2017), metafor for mix-
effect meta-analysis and meta-regression (Viechtbauer 2010), and MetaStan (Günhan B. K.
and Friede 2018). There are also R packages developed for network meta-analysis, which can
also deal with the problem discussed here, such as gemtc using JAGS for arm-based network
meta-analysis (van Valkenhoef and Kuiper 2016), pcnetmeta also using for contrast-based
network meta-analysis (L. Lin and Chu 2017) and nmaINLA using integrated nested Laplace
approximations (Sauter and Held 2015). One key advantage of RBesT is the EM step and
robustification step, which allows easy description of MAP priors and therefore makes analysis
easily reproducible. Also, for quantitative trial design and decision making, RBesT provides
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functions to evaluate operating characteristics for a new study and to perform the prediction
of probability of success at any time.
The organization of this paper is as follows. We will first describe the details of one motivating
example from a real clinical study. In Section 3, theoretical background on MAP approach and
robustification of MAP will be explained, followed by how these approaches can be applied
via RBesT to the example. Finally we close the paper with summary and discussions.
2. Example: Historical control in Phase II
One of the main use-cases of RBesT is the use of historical information in the analysis of
clinical trials. The goal is to reduce the trial (usually the control group) sample size while
maintaining its target power under the assumed true effect size of an alternative hypothesis.
The RBesT package facilitates the (i) prior derivation using MCMC, (ii) parametric (mixture)
approximation of the MAP prior and finally (iii) evaluation of the clinical trial design.
As an example we will use in the following the Novartis Phase II study in ankylosing spondyli-
tis comparing the Novartis test treatment secukinumab with placebo (Baeten et al. 2013).
The primary efficacy endpoint was a binary responder analysis for the percentage of patients
with a 20% response according to the Assessment of SpondyloArthritis international Society
criteria for improvement (ASAS20) at week 6. Eight historical trials, totaling 533 patients as
shown in table 1, were used to derive the MAP prior for the control arm.
Study 1 2 3 4 5 6 7 8
Patients (n) 107 44 51 39 139 20 78 35
Responders (r) 23 12 19 9 39 6 9 10
Table 1: Historical data used in Novartis Phase II study in ankylosing spondylitis. The data
set is available in the AS data frame as part of the RBesT package.
This Novartis Phase II trial was conducted using the MAP approach (before the availability
of RBesT). The trial used a Beta(11, 32) prior for the control arm and performed a 4 : 1
randomization ratio of active vs control patients. The final trial compared n = 24 (r = 15)
treated vs n = 6 (r = 1) control patients and declared success based on meeting the success
criterion defined as requiring that P (δ ≤ 0|y) > 0.95 holds. This example is discussed with
greater focus on the statistical aspects in the vignette “RBesT for a Binary Endpoint” part
of RBesT.
3. Bayesian evidence synthesis and prediction
Important decisions should arguably be evidence based, especially in medicine (Eddy 1990;
Wandel and Roychoudhury 2016). For example, decisions regarding design and analysis
of clinical trials are important for trial sponsors, patients, physicians and policy makers.
To support such decisions, relevant sources of information should be collected, appropri-
ately synthesized through meta-analytic approaches, and used to make predictions on the
planned target trial. We use the term meta-analytic-predictive (MAP) approach (Neuen-
schwander et al. 2010) to denote the synthesis of evidence from various sources, and the pre-
diction/extrapolation to the target. Although the MAP approach is useful in a broad range
4 Applying MAP Priors with RBesT
Y1 Y2 ... YJ
Y
*
θ1
θ2
θJ
θ
*
ψ
Target data
 p(Y |    )θ
* *
Source data
 p(Y |    )  j=1,...,Jθj j
Hierarchical model p(    ,    , ... ,    |    )θ
*
θ1 θJ ψ
Figure 1: MAP approach to evidence synthesis and prediction.
of applications, we consider here the medical setting (European Medicines Agency 2013).
Methodology for Bayesian evidence synthesis and prediction is well developed. Textbooks on
this topic include Stangl and Berry (2000), Spiegelhalter et al. (2004), Welton et al. (2012),
and Dias et al. (2018). Robust hierarchical models play a key role here, as explained in the
following Sections 3.1 and 3.2. Applications of the MAP approach are very diverse, and we
briefly discuss some settings in Section 3.3.
3.1. Meta-analytic-predictive methodology
Figure 1 schematically depicts the MAP approach for evidence synthesis and prediction.
Suppose that a sponsor plans a new clinical trial (the target, labeled by the star symbol). This
trial will generate data Y?, to be described by a statistical model p(Y?|θ?), with parameters
θ?. Usually, several relevant sources of information will be available, e.g. clinical trials in
the same or similar patient population, and with (partly) the same treatments. Each source
of information consists of data Yj , modeled by p(Yj |θj), with corresponding parameters θj ,
j = 1, ..., J . To borrow strength from the source information, a model is required that links
the parameters from both source and target: p(θ?, θ1, ..., θJ |Ψ), with hyper-parameters Ψ.
Such hierarchical models are very natural and convenient for the synthesis of the evidence
and the prediction to the target (Spiegelhalter et al. 2004). Within the Bayesian framework, a
prior for the hyper-parameters p(Ψ) is needed, which will be specific to the considered setting.
At the planning stage of the target trial, the data Y? are not available. Hence the posterior
distribution of the parameters p(θ?, θ1, ..., θJ ,Ψ|Y1, ..., YJ) is based on the source data only.
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The marginal posterior for the target parameter pMAP (θ?) = p(θ?|Y1, ..., YJ) is the prior
information for the target, called the MAP prior in the following.
Once the target data Y? are available, the posterior for θ? is p(θ?|Y?) ∝ p(Y?|θ?)pMAP (θ?).
Exactly the same posterior could also be obtained through a meta-analytic-combined (MAC)
approach, from p(θ?, θ1, ..., θJ ,Ψ|Y?, Y1, ..., YJ) (Schmidli et al. 2014).
An analytical derivation of the MAP prior is typically not possible, and hence Markov chain
Monte Carlo (MCMC) methods have to be used (Gelman et al. 2013). These generate a
large sample from the posterior distribution of the parameters, including θ?. However, an
approximate analytical description of the MAP prior facilitates communication and use with
standard software. Mixtures of normal distributions generally provide such an analytical
approximation (West 1993). When conjugate priors exist, mixtures of conjugate priors may
be used (Dallal and Hall 1983; Diaconis and Ylvisaker 1984). These are preferable, as they
allow analytical posterior calculations for the target trial in simple settings (O’Hagan and
Forster 2004; Schmidli et al. 2014).
3.2. Robustness to prior-data conflict
The MAP approach provides the prior for the target parameters as pMAP (θ?). Occasionally,
this MAP prior may turn out to be in conflict with the emerging target data Y?, despite great
care in the selection of relevant sources and in the specification of the model. The behavior of
the posterior distribution to prior-data conflicts is governed by the tails of the prior (O’Hagan
and Pericchi 2012). For example, conjugate priors are not heavy-tailed, and consequently the
posterior will always be a compromise between prior and data. However, MAP priors are
typically heavy-tailed, and are essentially discarded in case of prior-data conflict. This is a
desirable feature in most settings.
Although the MAP prior should be robust to prior-data conflict by accounting for heterogene-
ity, a faster reaction to prior-data conflicts may be achieved by adding a weakly-informative
mixture component pV (θ?) (Schmidli et al. 2014; Neuenschwander et al. 2016). The robusti-
fied MAP prior is:
pMAPr(θ?) = (1− w) pMAP (θ?) + w pV (θ?), (1)
where w may be interpreted as the prior probability that the source information is not relevant
for the target, expressing some degree of skepticism towards borrowing strength.
3.3. Applications
Methodology and diverse applications of the MAP approach in medicine are reviewed in Wan-
del et al. (2015), Schmidli et al. (forthcoming), and Neuenschwander and Schmidli (forthcom-
ing). Specific applications include comparison of several treatments though a network MAP
approach (Schmidli et al. 2013), the design and analysis of non-inferiority and biosimilar
clinical trials (Gamalo-Siebers et al. 2016; Mielke et al. 2018), and the use of external data
in adaptive clinical trials (Gsponer et al. 2014; Mütze et al. 2018). In the following, four
common applications are briefly described.
Random-effects meta-analysis
Random-effects meta-analyses of clinical trials are very common in medicine (Higgins and
Green 2008). These typically synthesize the evidence on the comparative effectiveness of two
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interventions in patients with a specific disease. Higgins et al. (2009) emphasize that both
the overall effect size and the prediction for the true effect in a new trial are important for
decision makers.
Sources of information are often J randomized clinical trials comparing a test and a control
treatment, with a continuous clinical endpoint. Data available from the j-th source trial are
taken from publications, and are usually the estimated effect Yj with standard error sej (taken
as exactly known). These data are modeled as Yj ∼ Normal(θj , se2j ). The parameters are
linked through a model: θ?, θ1, ..., θJ ∼ Normal(µ, τ2), with overall effect size µ and between-
trial standard deviation τ . The parameter θ? denotes the true effect in a new trial. Priors
for the hyper-parameters Ψ = (µ, τ) are e.g. a weakly informative Normal prior for µ and
a Half-Normal prior for τ . In case with few trials (i.e. J < 5), an appropriate choice of the
prior for τ is crucial (Gelman 2006; Friede et al. 2017,B). After having specified the priors,
RBesT may be used to obtain a sample from the posterior distribution of the parameters,
and to graphically and numerically summarize these.
Evaluation of probability of success
Clinical trials aiming to show the superiority of a test treatment over a control treatment are
often analyzed using a frequentist approach. The trial is considered a success, if a statistically
significant treatment effect is observed, with one-sided significance level α = 0.025. The
sample size of the trial is chosen such that a power of e.g. 80% is achieved, conditional
on a specific treatment effect θ?. However, the power does not provide the unconditional
probability of success (or assurance), as it ignores the uncertainty on the treatment effect. If
relevant source data on the treatment effect are available, the uncertainty on θ? is captured
by the MAP prior pMAP (θ?).
The probability of success (PoS) is the prior expectation of the power, averaged over the MAP
prior (O’Hagan et al. 2005).
PoS =
∫
CP(θ?) pMAP (θ?) dθ? , (2)
where CP(θ?) is the conditional power function, i.e. the probability of success conditional
on an assumed true treatment effect. From a MCMC sample θ(1)? , ..., θ(M)? of the MAP prior
the PoS may be calculated as 1/M∑mCP(θ(m)? ). Alternatively, the MAP prior may be
approximated by a mixture of normal priors with RBesT, and PoS can be evaluated by
numerical integration.
PoS evaluations are also relevant for decision makers at interim analyses of clinical trials.
If the PoS (or predictive power) at interim is low, the trial may be stopped early to avoid
unnecessary exposure of patients to ineffective treatments and to save resources (Spiegelhalter
et al. 1986; Schmidli et al. 2007; Neuenschwander et al. 2016). For these interim analyses, the
MAP prior is updated with the interim data.
Extrapolation
New treatments are typically first investigated in adult patients, before starting clinical trials
in children. For many diseases and treatments, a similar effect may be expected for children
and adults, using a possibly modified children version of the treatment (e.g. dosing based
on body weight). Borrowing strength from the available adult trials should therefore always
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be considered (FDA’s Center for Devices and Radiological Health (CDRH) and Center for
Biologics Evaluation and Research (CBER) 2015; European Medicines Agency 2018). The
MAP approach may be used for extrapolation (Wandel et al. 2017; Röver et al. 2019), although
alternative methods are also available (Gamalo-Siebers et al. 2017; Wadsworth et al. 2018).
The source data are usually J randomized clinical trials in adults comparing test and control
treatment. These can be summarized with a random-effects meta-analysis as described above,
which provides the MAP prior for the treatment effect in a new trial in adults pMAP (θ?). In
some settings essentially the same treatment effect in adults and children may be expected,
based on a scientific understanding of the disease and the mode-of-action of the treatment.
Hence, the MAP prior for adults may also be used for a new trial in children. Skepticism on the
relevance of the adult data may be expressed by robustifying the MAP prior (Section 3.2). In
simple settings, RBesT can be used to derive the MAP prior, robustify it, evaluate frequentist
operating characteristics of the trial in children, and finally obtain the posterior distribution
of the treatment effect in children, once results from the children trial are available.
Historical controls
In many disease areas, multiple randomized controlled trial (RCT) have been conducted,
with the same control group (e.g. placebo) but different test treatments. When planning to
investigate a new test treatment in a RCT, the question arised whether one could borrow
strength from the historical control data (Viele et al. 2014). In this setting, the sources of
information are the control data from J trials. For a clinical endpoint, the control mean from
the jth trial may be modeled as Yj ∼ Normal(θj , se2j ), with true control mean θj , and standard
error sej (taken as exactly known). A model is used to provide the link to the true control
mean in the new trial θ? as: θ?, θ1, ..., θJ ∼ Normal(µ, τ2). With appropriate priors for the
hyper-parameters, the MAP prior pMAP (θ?) is derived, and used as the informative prior for
the control group in the new trial. Again, it is often advisable to robustify the MAP prior in
case of some doubt on the relevance of the historical control information (Section 3.2). RBesT
may be used for MAP prior derivation, evaluation of frequentist operating characteristics and
the final analysis. An example data set is described in Section 2 and in Section 4 we present
how RBesT facilitates the use of historical control information in clinical trials.
Use of the MAP approach in historical control settings has also been described for data
modeled by the one-parameter exponential family (Schmidli et al. 2014), count data (Gsteiger
et al. 2013), recurrent event data (Holzhauer et al. 2018), time-to-event data (Holzhauer 2017)
and variance data (Schmidli et al. 2017).
4. Application
In the following the use of RBesT is explained for the example introduced in section 2. The
RBesT package facilitates the (i) prior derivation using MCMC, (ii) parametric (mixture)
approximation of the MAP prior and finally (iii) evaluation of the clinical trial design.
4.1. Prior derivation
The statistical models implemented in the package follow the standard generalized linear re-
gression modelling conventions and are implemented with the gMAP function mostly analogous
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as in the R glm command of the stats package. The supported sampling distributions are
normal (with known sampling standard deviation σ), binomial and Poisson. These use the
canonical link functions of the identity, logit and log link, respectively. The gMAP function
call for the secukinumab trial is:
set.seed(35667)
map_mcmc <- gMAP(cbind(r, n-r) ~ 1 | study, family=binomial, data=AS,
tau.dist="HalfNormal", tau.prior=1, beta.prior=cbind(0, 2))
The first argument is the formula argument which specifies a two-column matrix as response
for a binary endpoint and contains in the first column the number of responders r and in
the second column the number of non-responders n − r. The response is modeled using an
intercept only here, but covariates can be specified using standard R formulae syntax. The
last element of the formula is the grouping factor, separated by a vertical bar. The grouping
factor defines what constitutes a trial in the data set. If no grouping factor is specified,
then each row in the input data set is interpreted as a group. The next argument is the
family argument which specifies the sampling distribution. It is strongly recommended to
use data and pass a data.frame to it where all data for the model is stored (otherwise the
environment will be searched for the respective columns). Finally, the priors of the model are
specified. As the between-trial heterogeneity parameter τ is of particular importance for a
meta-analysis, the gMAP function allows the user to choose the distributional class for the τ
parameter with the tau.dist argument whereas the regression coefficients β are restricted to
Normal priors. The arguments tau.prior and beta.prior both take a two column argument
with the convention that each row corresponds to the respective parameter and the columns
correspond to respective parameters of the prior distribution. Whenever a prior distribution
for τ only needs a single parameter, a vector can be given has well, which is the case for the
HalfNormal distribution used here with a standard deviation of 1. For the beta.prior, the
first and second column correspond to the means and standard deviations of the normal prior
distributions, respectively.
Internally the gMAP function uses Stan via the rstan package for sampling from the posterior
distribution. The diagnostics of the MCMC sampler as provided by Stan are automatically
inspected and potential issues are reported with a warning. The gMAP function returns an S3
object, which can then be further processed by standard R modeling functions. The default
method
print(map_mcmc)
## Generalized Meta Analytic Predictive Prior Analysis
##
## Call: gMAP(formula = cbind(r, n - r) ~ 1 | study, family = binomial,
## data = AS, tau.dist = "HalfNormal", tau.prior = 1, beta.prior = cbind(0,
## 2))
##
## Exchangeability tau strata: 1
## Prediction tau stratum : 1
## Maximal Rhat : 1
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##
## Between-trial heterogeneity of tau prediction stratum
## mean sd 2.5% 50% 97.5%
## 0.3790 0.2090 0.0431 0.3540 0.8650
##
## MAP Prior MCMC sample
## mean sd 2.5% 50% 97.5%
## 0.2590 0.0858 0.1130 0.2480 0.4670
shows a short summary of the gMAP analysis. The derived MAP prior corresponds to the
intercept-only model of the fitted statistical model (relevant when using covariates) and is
given on the response scale by default as opposed to the link scale of log-odds in this case.
More information of the model estimates is available with the summary method. Importantly,
the plot method provides key graphical summaries of the gMAP analysis:
model_plots <- plot(map_mcmc)
names(model_plots)
## [1] "densityThetaStar" "densityThetaStarLink" "forest_model"
The density estimate plot on the response or link scale of the MAP prior shows each fitted
chain (by default 4 chains are used) separatley. The overlayed display by chain allows to assess
graphically the convergence of the MCMC analysis, since each chain must have sampled the
same density resulting in very similar densities. As key diagnostic plot we recommend to
inspect the forest_model as shown in Figure 2(a). The plot gives a graphical summary of
the MAP analysis and can serve as a fast check for coding errors.
4.2. Parametric mixture prior derivation
The MAP prior, represented numerically with a large MCMC simulation sample, can be
approximated with a parametric representation with the automixfit function. This function
fits a parametric mixture representation using expectation-maximization (EM) algorithm.
When calling this function with a gMAP analysis object, the EM algorithm is run on the MAP
prior MCMC values on the response scale (as opposed to the transformed link scale). The
distributional class of the fitted mixture densities depends on the sampling distribution of the
family argument. For the gaussian, binomial and poisson family a mixture of normal, beta
and gamma distributions are fitted with the EM algortihm, respectivley. These choices allow
RBesT to take advantage of analytical results as the respective likelihood-prior combinations
are conjugate to one another.
The EM algorithm requires a pre-specified number of components, which is chosen from
automixfit automatically through the use of AIC. The function fits parametric mixture
models of increasing complexity with up to four components and then selects the one with
the lowest AIC. The output below shows the log-likelihood results for the selected mixture
model, as well as the mixture components of the beta mixture. All mixtures are represented in
RBesT using for each mixture component k a triplet (w, a, b)k which correspond to the weight
w of the component, the first standard parameter a and the second standard parameter b of
the respective density. Please refer to the overview table 2 for further details.
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(a) Diagnostic plot of gMAP analysis
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Figure 2: Recommended diagnostic plots. (a) Shown are the per-trial point estimates (light
dot) and the 95% frequentist confidence intervals (dashed line) and the model derived median
(dark point) and the 95% credible interval of the meta-analytic model. In addition the model
derived typical parameter estimate and the MAP estimate is shown. (b) Overlay of the
MCMC histogram of the MAP prior as obtained from gMAP and the respective parametric
mixture approximation as determined from automixfit.
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map <- automixfit(map_mcmc)
print(map)
## EM for Beta Mixture Model
## Log-Likelihood = 4471.393
##
## Univariate beta mixture
## Mixture Components:
## comp1 comp2
## w 0.6270981 0.3729019
## a 17.0007087 3.6667131
## b 52.4947716 9.2845241
To consider the quality of the EM fit we recommend to compare the MCMC sample with
the parametric mixture density in a graphical manner. In Figure 2(b) the output of the
plot method is shown for the generated mix plot, which overlays the fitted mixture density
marginal with a histogram of the MCMC sample. In rare cases the response scale can be
inadequate to compare the parametric mixture density appropriately (for example, if the
response rate is very small or very large):
em_diagnostic <- plot(map)
print(em_diagnostic$mix) ## Shown in Figure 2(b)
print(em_diagnostic$mixdens) ## Not shown
em_diagnostic_link <- plot(map, link="logit")
print(em_diagnostic_link$mix) ## Not shown, same as 2(b) on logit scale
Once the user has derived a parametric mixture representation for the MAP prior, the RBesT
package provides additional functions to further investigate as shown in the overview Table 2.
In the following we discuss the key functions needed in the context of informative prior
derivation from historical data.
As the goal is to reduce the required sample size in a future trial, the informative MAP prior
enables unequal randomization of active vs control. In the ankylosing spondylitis example a
4:1 randomization ratio was chosen. The ess function provides approximations to the effective
sample size of a given prior for various methods. The effective sample size of the MAP prior
gives a rough guide by how much the sample size can be reduced when using the respective
frequentist power calculation as a reference, for example.
Instead of using the MAP prior directly in a new study, we recommend to robustify the prior
with a weakly-informative component (equation 1 of Section 3.2) as follows:
map_robust <- robustify(map, weight=0.2, mean=0.5)
RBesT offers many functions which facilitate to explore the implications of an informative
prior. For example, the predictive distribution of the data in a new trial can easily be derived
with the preddist command. While the MAP prior is the predictive distribution of the mean
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parameter for a new trial and accounts for parameter uncertainty and between-trial hetero-
geneity, the predictive distribution of data accounts in addition for sampling uncertainty. For
beta mixture densities the respective predictive distribution is the BetaBinomial mixture dis-
tribution. This can be used to illustrate possible outcomes in a future trial or to calculate
the Bayes factor of observed data with respect to the prior.
Moreover, RBesT provides the postmix command which updates a prior with the data as
observed and computes analytically the posterior mixture distribution. For two-sample cases
we are often interested in the difference distribution of two densities (representing a treatment
difference). In RBesT the difference distribution of mixtures of the same class is supported
through the use of the convolution theorem which allows for an accurate evaluation. The ta-
ble 2 summarizes all functions available for parametric mixtures supported in RBesT. Further
details are available in the help files for each function.
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Function Name Use Notes
c(w, a, b) Defines a component of a mixture distribution.
Specifies for each component its weight, the first
and second standard parameter
normal densities use mean and standard devia-
tion; beta densities use α and β; gamma densi-
ties use shape and rate
mn2norm mn2beta
mn2gamma
Maps to standard parametrization given mean
and number of observations
ms2beta ms2gamma Maps to standard parametrization given mean
and standard deviation
mixnorm mixbeta
mixgamma
Creates supported base mixture distribution ob-
jects
for normal densities the attribute sigma sets the
known sampling standard deviation; for gamma
densities a likelihood attribute sets the likeli-
hood the density is intended to be used with
mixcombine Combines mixture distributions
(d/p/q/r)mix density/distribution/quantile/random number
generation
quantile function uses numerical search
(optimise and as fallback uniroot)
robustify Add weakly-informative component to mixture
(d/p/q/r)mixdiff Difference of two mixture distribution via con-
volution
uses convolution theorem; for normal mixtures
analytically exact results
ess Calculates the effective sample size for a mixture
prior
elir (default), moment matching and morita
method; refer to appendix B
postmix Calculates posterior mixture distribution for
data and prior mixture
uses analytically exact results
preddist Returns the predictive mixture distribution
decision1S_boundary
decision2S_boundary
Calculates critical decision boundary refer to appendix C
oc1S oc2S Calculates conditional power refer to appendix C
pos1S pos2S Calculates probability of success refer to appendix C
summary Produces descriptive statistics for mixture
plot Produces diagnostic plots of gMAP analyses, EM
fits and mixtures distributions
Table 2: Overview on functions in RBesT defined for parametric mixtures.
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4.3. Trial design evaluation
Once a parametric mixture MAP prior has been derived, it is crucial to understand its in-
fluence on the statistical analysis of a clinical trial. In the context of the historical control
example the goal is commonly to reduce the control group sample size while maintaining
adequate power for trial success under the alternative hypothesis which assumes some true
effect size. The main focus here is the evaluation of the (frequentist) operating characteristics
of the trial design with respect to achieving trial success.
RBesT follows a modular, step-wise approach for design evaluation. First, a success criterion
is defined, then the design of the trial is specified and finally the desired evaluation of the
trial can be conducted for possible scenarios of interest. The success criterion supported are
restricted to one-sided criterion’s which are referred to as decision functions. These can be
set up for one-sample (decision1S) and two-sample (decision2S) situations. In RBesT the
decision functions can be set up to require that multiple critical probability thresholds and
quantiles for the difference distribution have to be met in the two-sample case while these
thresholds are applied directly to the posterior density in the one-sample case. This enables
evaluation of so-called dual criterion designs (Roychoudhury et al. 2018) which evaluate a
statistical confidence criterion (high confidence in a positive/negative difference) and a mini-
mally observed treatment difference (observed median difference being greater/smaller than
some value). For the ankylosing spondylitis trial, success was declared whenever the poste-
rior treatment difference is positive with a probability which exceeds 95%. In RBesT this is
expressed as:
# decision function as used in the trial
success <- decision2S(0.95, 0)
# an alternative which demands in addition to see at least
# a median difference of at least 10%
success_dual <- decision2S(c(0.95, 0.5), c(0, 0.1))
The returned object represents the decision function and is a binary function. It takes as
arguments two mixture densities (those will be the mixture posteriors) and returns 1 whenever
the condition for success on the difference distribution of the two mixture densities is fulfilled
and 0 otherwise. Optionally, the success criterion allows for transformation of the input
mixture distributions prior to forming the difference distribution using the link argument.
The log and logit link enable relative risk and log odds-ratio success criterion to be evaluated
with RBesT.
The next step is to define the design of the trial using the operating characeristics function
oc2S (or oc1S for a one-sample case). The design of the trial includes the priors for each
arm, the total sample size per arm and the decision function for trial success. To evaluate,
for example, the impact a robust MAP prior has on the frequentist operating characteristics
compared to the respective non-robust design, one can may use:
## prior used for treatment in trial
treat_prior <- mixbeta(c(1, 1/2, 1))
## explore different trial designs
design_nonrobust <- oc2S(map , treat_prior, 6, 24, success)
design_robust <- oc2S(map_robust, treat_prior, 6, 24, success)
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The oc2S function returns a binary function which is finally used to calculate the frequency
of trial success as a function of an assumed truth for each arm. For the binomial sampling
distribution, the function takes assumed true response rates θ1 and θ2. Whenever these two
are set to the same numerical value θ = θ1 = θ2, the scenario of no treatment difference is
evaluated which would be referred to a type-I error in respective Frequentist trial analysis.
Setting θ1 to a plausible control response rate and varying θ2 as a function of the difference
δ = θ2− θ1 gives the desired power of the trial. The functions take vectors of equal length as
arguments so that we can evaluate the type-I over large parameter ranges as:
theta <- c(0.25, 0.5, 0.75)
round(design_nonrobust(theta, theta), 3)
## [1] 0.020 0.341 0.795
round(design_robust(theta, theta), 3)
## [1] 0.018 0.190 0.173
Here we see that the Bayesian design with informative priors does not control the type-I
error and that the error rate depends on the actual parameter value. However, the 97.5%
quantile of the MAP prior is approximatley 0.48 such that response rates greater than this
would be very unusual. Given that RBesT is fast and accurate for these calculations, it is
recommended to use graphical plots in addition to tables to visualize the (error) rates of
interest as demonstrated in the vignettes of RBesT.
In addition to the operating characteristics functions RBesT also provides respective func-
tions to evaluate the probability of success with pos2S and pos1S. These functions allow to
account for uncertainty in the assumed true parameter values. They pos2S (pos1S) require as
arguments the same trial design specification arguments as the oc2S (oc1S) functions. The
returned functions take as arguments mixture densities which represent uncertainty in the
respective parameter of each arm.
Internally, all trial design calculations use analytical results wherever possible. This makes
RBesT very accurate and fast in evaluating the design properties of trials. A key quantitiy
calculated is the critical decision boundary determined by the success criterion and the trial
design. At the critical outcome boundary the success criterion changes its value between 0 and
1. While in the one-sample case this corresponds to a single value, it is a function of the out-
come in the second sample in the two-sample case. As the decision boundary can be useful for
other applications, the boundary can be obtained with the functions decision2S_boundary
(decision1S_boundary). These are also useful when communicating various data scenarios
and their respective decisions to non-statisticians like clinical teams. For more details please
refer to the appendix.
5. Summary
In this paper, we introduced the RBesT package which implements the MAP approach via
MCMC sampling algorithms for a number of common sampling and prior distributions. In-
corporating historical data in clinical studies has various advantages, such as reducing the
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number of subjects randomized to a control arm or getting more precise information for deci-
sion making. Incorporation of historical data should lead to more ethical and efficient clinical
trials.
The MAP approach is a hierarchical modeling method allowing heterogeneity between histor-
ical trials, which can incorporate historical data in a meta analytic framework. The RBesT
package allows for easier implementation of MAP priors. After selection of appropriate histori-
cal information, RBesT facilitates the prior derivation using MCMC, the parametric (mixture)
approximation of the MAP prior and finally the evaluation of the clinical trial design.
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A. Parametric mixture inference
In RBesT the expectation maximization (EM) algorithm is used to find parametric mixture
approximations to the numerical representation of the MAP prior. Thus, we consider in this
section as data Y the MCMC sample representing the MAP prior (or any other MCMC
sample). Direct application of maximum likelihood is numerically problematic, since the log-
likelihood for a mixture prior, log p(Y |w,a, b) = ∑Ni=1 log∑Kk=1wk pk(Yi|ak, bk), involves the
sum over the log of the component densities wk pk(Yi|ak, bk). The inner summation is on the
natural scale and is required as we do not know the component k which a data item Yi is a
member of. However, extending the observed data (Y ), also referred to as incomplete data,
to the so-called complete data (Y ,Z) leads to a numerically stable problem. The unobserved
data Z is defined as the latent component indicator such that Zi,k is 1 whenever data item i is
part of component k and 0 otherwise. The extended problem is related to the original through
marginalization, p(Y |w,a, b) = EZ [p(Y ,Z|w,a, b)]. However, the extended log-likelihood
factorizes in the usual way
log p(Y ,Z|w,a, b) =
N∑
i=1
K∑
k=1
Zi,k [log(wk) + log pk(Yi|ak, bk)] .
The EM algorithm begins with a fixed number of mixture components K and an initial guess
of all parameters. The initial guess of the parameters is achieved with the k nearest neighbors
(knn) algorithm in RBesT with the exception of the normal mixture case as detailed below.
The parameter vector (w,a, b) is then updated iteratively. The nth iteration of the EM
consists of first performing the expectation (E) step and then the maximization (M) step
which updates the parameter vector for the next iteration. These EM steps are then repeated
until convergence to a maximum of the log-likelihood. While it is guaranteed that in each
iteration the log-likelihood is always increased, the EM algorithm may only find a local rather
than a global extremum.
E-step The E-step calculates the posterior probability for the latent indicators p(Z|Y ,w,a, b)
in order to compute the expected posterior mean weights
E[Zi,k] =
wk p(Yi|ak, bk)∑
k wk p(Yi|ak, bk)
= γ(Zi,k).
The expression γ(Zi,k) is often referred to as the responsibility of mixture component k for
data item i. The overall responsibility of mixture component k
Nk =
N∑
i=1
γ(Zi,k)
can be interpreted as the number of data items belonging to mixture component k. Finally, the
E-step computes the expectation of the complete log-likelihood with respect to Z conditional
on the parameter vector of the current nth iteration,
EZ|wn,an,bn [log p(Y ,Z|w,a, b)] =
N∑
i=1
K∑
k=1
γ(Zi,k) [log(wk) + log pk(Yi|ak, bk)]
= Q(w,a, b|wn,an, bn)
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M-step The M-step then proceeds by finding a new parameter vector through maximization
(wn+1,an+1, bn+1) = arg max
w,a,b
Q(w,a, b|wn,an, bn).
The updated weights are constrained to sum to one. Maximization with this constraint is
achieved through Lagrange multipliers and leads for the updated weights to the solution
wn+1k =
Nk
N
.
To find the maximum with respect to the parameters of each component k, we take the
gradient (∂ak , ∂bk) of Q(w,a, b|wn,an, bn) and equate these to zero.
Normal mixtures For normal mixtures RBesT implements internally a multi-variate nor-
mal EM, but only exposes the uni-variate functionality at the moment. Empirically we
observed that the normal EM algorithm is easily trapped into local extrema which is caused
by the commonly heavy tailed distributions of MAP priors. For this reason, we initialize the
normal EM with the result of a Student-t EM procedure as described in Peel and McLachlan
(2000). The Student-t EM is itself initialized with k nearest neighbors. The maximization
equations can be solved analytically in the normal mixture case,
µk =
1
Nk
N∑
i=1
γ(Zi,k)Yi
Σk =
1
Nk
N∑
i=1
γ(Zi,k) (Yi − µk) (Yi − µk)′.
The analytical solution is a weighted mean and covariance estimate with the weight for each
data item Yi equal to γ(Zi,k)/Nk.
Beta mixtures For beta mixture distributions we are lead to the joint equation system of
(see also Ma and Leijon 2009)
ψ(ak)− ψ(ak + bk) = 1
Nk
N∑
i=1
γ(Zi,k) log(Yi)
ψ(bk)− ψ(ak + bk) = 1
Nk
N∑
i=1
γ(Zi,k) log(1− Yi).
Here ψ(x) is defined as ∂x log(Γ(x)). This equation system is solved simultaneously for ak
and bk through numerical minimization.
Gamma mixtures With gamma mixtures the algebraic equation system
ψ(ak)− log(bk) = 1
Nk
N∑
i=1
γ(Yi,k) log(Yi)
ak
bk
= 1
Nk
N∑
i=1
γ(Zi,k)Yi
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is obtained. This system can be reduced to a single equation, which is again solved through
numerical minimization.
B. Effective sample size
The effective sample size is an approximate measure for the number of observations a prior is
equivalent to. In the setting of conjugate likelihood-prior pairs without mixtures the standard
parameters can be cast into an effective sample size. However, this is not the case for mixture
priors and RBesT implements three approaches:
elir The expected local information ratio has been proposed in Neuenschwander et al. (2019)
and is a predictively consistent effective sample size measure. The predictive consistency
requires that the effective sample size of the prior is equal to the average effective sample
size of the respective posterior of this prior after simulation of m samples from the
predictive prior distribution and subtracting m from the averaged posterior effective
sample size. The method is neither liberal nor conservative and is the default method
in RBesT.
morita The method from Morita et al. (2008) evaluates the curvature of the prior at a refer-
ence point (mode, median or mode) and compares this against the expected curvature of
a posterior of a variance inflated prior which is updated with m samples from the prior
predictive of the prior. The m is chosen to minimize the difference in curvature. Since
the Morita method evaluates the prior at a single point, the approach can be sensitive
to the curvature at this point and has been observed to report relatively liberal effective
sample sizes when used with mixture priors.
moment The moment based approach matches the mean and the variance of a given prior
to its respective canonical prior from which the effective sample size can be obtained
directly from the standard parameters. This approach has been found empirically to
report very conservative (low) effective sample sizes.
The key expressions involved in the effective sample size calculations is the prior information
i(p(θ)) = −∂2θ log(p(θ))
and the Fisher information
iF (θ) = EY1|θ [i(p(Y1|θ))] = −EY1|θ
[
∂2θ log(p(Y1|θ)))
]
.
The Fisher information is derived from the sampling distribution, but the second derivative
of the log mixture prior density with K components, defined as
p(θ|w,a, b) =
K∑
k=1
wk pk(θ|ak, bk),
needs some considerations for a numerically stable evaluation. It is key to evaluate the log
density instead of the density on the natural scale whenever possible. We will in the following
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suppress the weights and standard parameters of p(θ) and pk(θ) for simplicity. Using the
equality ∂θp(θ) = p(θ) ∂θ log(p(θ)) one finds that the prior information for a mixture is
i(p(θ)) = 1
p(θ)2
[
K∑
k=1
wk pk(θ) ∂θ log pk(θ)
]2
− 1
p(θ)
K∑
k=1
wk pk(θ)
[
(∂θ log pk(θ))2 + ∂2θ log pk(θ)
]
. (3)
The table 3 lists all the main expressions required for the supported conjugate likelihood-prior
pairs in RBesT.
Sampling distribution Fisher information Prior density Prior information
p(Y |θ) iF (θ) pk(θ|a, b) i(pk(θ))
Normal(Y |θ, σ2) σ−2 Normal(θ|m, s2) s−2
Binomial(Y |θ, n) nθ (1−θ) Beta(θ|a, b) a−1θ2 + b−1(1−θ)2
Poisson(Y |θ) θ−1 Gamma(θ|a, b) a−1
θ2
Exp(Y |θ)† θ−2 Gamma(θ|a, b) a−1
θ2
Table 3: Overview on supported conjugate likelihood-prior pairs supported in RBesT. †Note
that for the exponential sampling distribution only the effective sample size calculations are
supported as of RBesT 1.4-0.
C. Informative prior evaluation
In RBesT one-sided decision functions with multiple criteria are supported for one and two
sample cases. The decision functions are indicator functions through thresholding density
distributions such that critical quantiles must exceed predefined probability thresholds. De-
noting with H(x) the Heaviside step function, which is 0 for x ≤ 0 and 1 otherwise, the
decision functions are defined as
D(p(θ)) =
∏
i
H(P (θ ≤ qi,c)− pi,c) one sample,
D(p1(θ1), p2(θ2)) =
∏
i
H(P (θ1 − θ2 ≤ qi,c)− pi,c) two sample.
In the two-sample case the difference distribution of p1(θ1) and p2(θ2) is thresholded.
Critical decision boundary With the design of a trial the priors and the sample size per
sample is defined and these determine the critical decision boundary of the decision function,
Dc = sup
y
{D(p(θ|y)) = 1} = yc one sample,
Dc,1(y2) = sup
y1
{D(p1(θ1|y1), p2(θ2|y2)) = 1} two sample.
While for the one sample cases the decision boundary is a single value, Dc = yc, the decision
boundary is a function of the outcome in one of the samples (by convention the second
sample), Dc,1(y2).
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Conditional power The critical decision boundary is used in RBesT to simplify the con-
ditional power calculation in the following manner,
CP(θ) =
∫
D(p(θ′|y)) p(y|θ) dy =
∫ yc
−∞
p(y|θ) dy
= P (y ≤ yc|θ) one sample,
CP(θ1, θ2) =
∫∫
D(p1(θ′1|y1), p2(θ′2|y2)) p1(y1|θ1) p2(y2|θ2) dy1 dy2
=
∫
P1(y1 ≤ Dc,1(y2)|θ1) p2(y2|θ2) dy2 two sample.
Therefore, the conditional power simplifies in the one sample case to evaluation of the cu-
mulative density function corresponding to the sampling distribution and in the two sample
case the integration is simplified to a one dimensional integral instead of a two dimensional
one. For the case of a binomial sampling distribution the calculations are carried out exactly.
With normal and Poisson endpoints the respective integrals are evaluated with quadrature
integration on a domain which corresponds to 1−  ( = 10−6 by default) of probability mass.
Probability of success The probability of success as defined in equation 2 of Section 3.3.2
results in a double (triple) integral for the one (two) sample case. To simplify this, the prior
predictive distribution of the prior p(θ),
p(y) =
∫
p(y|θ) p(θ) dθ,
is used. The prior predictive distribution is available in analytic form and allows to re-arrange
the evaluation of the equation 2 as
PoS =
∫
CP(θ) p(θ) dθ =
∫∫
D(p(θ′|y)) p(y|θ) p(θ) dθ dy =
∫
D(p(θ′|y)) p(y) dy.
This re-arrangement holds for the two sample case respectively. This leads to the same
calculations as previously for the operating characteristics with the only difference in that
the sampling distribution, p(y|θ), is replaced by the predictive distribution of the prior, p(y).
For the two sample case the integration is performed using numerical integration while for
the one sample case the cumulative distribution function of the predictive is evaluated.
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